Evidence map›Paper›PMID 31372333›Full record

ReviewJournal of bone oncology2019

The role of CXCR4 in multiple myeloma: Cells' journey from bone marrow to beyond.

Tomalika Rahmat Ullah

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of bone oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Optimal acquisition time of [EJNMMI research · 2026
    Article
  6. Article
  7. Anti-myeloma activity of the CXCR4 antagonist WZ811.Journal of molecular medicine (Berlin, Germany) · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Tomalika Rahmat UllahHudson Institute of Medical Research, 27-31 wright street, Clayton VIC 3168, Australia.
Hudson Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXCR4 is a pleiotropic chemokine receptor which acts through its ligand CXCL12 to regulate diverse physiological processes. CXCR4/CXCL12 axis plays a pivotal role in proliferation, invasion, dissemination and drug resistance in multiple myeloma (MM). Apart from its role in homing, CXCR4 also affects MM cell mobilization and egression out of the bone marrow (BM) which is correlated with distant organ metastasis. Aberrant CXCR4 expression pattern is associated with osteoclastogenesis and tumor growth in MM through its cross talk with various important cell signalling pathways. A deeper insight into understanding of CXCR4 mediated signalling pathways and its role in MM is essential to identify potential therapeutic interventions. The current therapeutic focus is on disrupting the interaction of MM cells with its protective tumor microenvironment where CXCR4 axis plays an essential role. There are still multiple challenges that need to be overcome to target CXCR4 axis more efficiently and to identify novel combination therapies with existing strategies. This review highlights the role of CXCR4 along with its significant interacting partners as a mediator of MM pathogenesis and summarizes the targeted therapies carried out so far.

Indexed as

AMC, Angiogenic monomuclear cellsBM, Bone marrowBMSC, Bone marrow stromal cellsCAM-DR, Cell adhesion‐mediated drug resistanceCCR–CC, Chemokine receptorCCX–CKR, Chemo Centryx–chemokine receptorCD4, Cluster of differentiation 4CL—CC, Chemokine ligandCNS, Central nervous systemCSCs, Cancer stem cellsCTAP-III, Connective tissue-activating peptide-IIICXCL, CXC chemokine ligandCXCR, CXC chemokine receptorEGF, Epidermal growth factorEMD, Extramedullary diseaseEPC, Endothelial progenitor cellsEPI, Endogenous peptide inhibitorERK, Extracellular signal related kinaseFGF, Fibroblast growth factorG-CSF, Granulocyte colony-stimulating factorGPCRs, G protein-coupled chemokine receptorsHCC, Hepatocellular carcinomaHD, Hodgkin's diseaseHGF, Hepatocyte growth factorHIF1α, Hypoxia-inducible factor-1 alphaHIV, Human Immunodeficiency VirusHMGB1, High Mobility Group Box 1HPV, Human papillomavirusHSC, Hematopoietic stem cellsIGF, Insulin-like growth factorJAK/STAT, Janus Kinase signal transducer and activator of transcriptionJAM-A, Junctional adhesion molecule-AJNK, Jun N-terminal kinaseMAPK, Mitogen Activated Protein KinaseMIF, Macrophage migration inhibitory factorMM, Multiple myelomaMMP, Matrix metalloproteinasesMRD, Minimal residual diseaseNHL, Non-Hodgkin's lymphomaOCL, OcteoclastOPG, OsteoprotegerinPI3K, phosphoinositide-3 kinasePim, Proviral Integrations of Moloney virusPKA, protein kinase APKC, Protein kinase CPLC, Phospholipase CRANKL, Receptor activator of nuclear factor kappa-Β ligandRRMM, Relapsed/refractory multiple myelomaSFM-DR, Soluble factor mediated drug resistanceVEGF, Vascular endothelial growth factorVHL, Von Hippel-LindauWHIM, Warts, Hypogammaglobulinemia, Infections, and MyelokathexisWM, Waldenström macroglobulinemia

Identifiers

PMID31372333
PMCPMC6658931
OpenAlexW2958089272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.